David Horowitz > Hogan Lovells US LLP > Washington DC, United States > Lawyer Profile
Hogan Lovells US LLP Offices

COLUMBIA SQUARE
555 THIRTEENTH STREET, NW
WASHINGTON DC 20004
DISTRICT OF COLUMBIA
United States
- Firm Profile
- Go to...
David Horowitz

Work Department
Pharmaceuticals and Biotechnology
Position
Partner
Career
After 25 years in senior legal and policy positions at the U.S. Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS), including HHS Deputy General Counsel and FDA Director of Drug Compliance, David Horowitz achieves results for clients by helping them anticipate, communicate, and work effectively with regulators and policy makers.
He represents life sciences clients on FDA compliance and regulatory policy issues, including responding to FDA warnings and compliance actions, import and export issues, current good manufacturing practice (GMP) requirements, drug shortages, registration/listing, pharmacy/compounding issues, Over-the-Counter (OTC) drugs, and user fees. His insight into FDA’s requirements, statements, and actions allows him to identify solutions that satisfy the clients’ business needs within FDA’s regulatory framework.
Prior to joining Hogan Lovells, he served as Deputy General Counsel at HHS, advising the Secretary of HHS on FDA issues and overseeing the lawyers at FDA, CDC and NIH. Before this role, he worked for over 17 years in senior legal and compliance positions at FDA, including as Director of Compliance for the Center for Drug Evaluation and Research (CDER), Assistant Commissioner for Policy, and Associate Chief Counsel for Drugs.
Languages
English
Education
J.D., University of Virginia School of Law; B.A., Brown University, magna cum laude
Top Tier Firm Rankings
- Transport > Aviation and air travel: litigation and regulation
- M&A/corporate and commercial > Corporate governance
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Industry focus > Education
- Government > Government relations
- Healthcare > Life sciences
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Telecoms and broadcast: regulatory
- Media, technology and telecoms > Telecoms and broadcast: transactions
- International trade and national security > Trade remedies and trade policy
Firm Rankings
- Antitrust > Cartel
- International trade and national security > CFIUS
- International trade and national security > Customs, export controls and economic sanctions
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Energy > Energy regulation: electric power
- Energy > Energy regulation: oil and gas
- Environment > Environment: litigation
- Environment > Environment: regulatory
- Government > Government contracts
- Healthcare > Health insurers
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- International trade and national security > National Security
- Transport > Rail and road: litigation and regulation
- Healthcare > Service providers
- Tax > US taxes: non-contentious
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- Finance > Capital markets: global offerings
- Energy > Energy litigation: oil and gas
- Tax > International tax
- Antitrust > Merger control
- Finance > Restructuring (including bankruptcy): corporate
- Media, technology and telecoms > Technology transactions
- Antitrust > Civil litigation/class actions: defense
- Finance > Fintech
- Real estate > Real estate finance
- Finance > Structured finance: derivatives and structured products
- Intellectual property > Trademarks: litigation
- M&A/corporate and commercial > Venture capital and emerging companies
- Investment fund formation and management > Private equity funds (including venture capital)
- Real estate > Real estate
- Intellectual property > Patents: litigation (full coverage)